A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)
Status:
Completed
Trial end date:
2014-07-16
Target enrollment:
Participant gender:
Summary
This study will investigate the safety and tolerability of combination therapy with MK-2206
and AZD6244 (selumetinib) and determine the maximum tolerated dose (MTD) and recommended
Phase 2 dose (RPTD) for this drug combination in the treatment of participants with locally
advanced or metastatic solid tumors. Preliminary efficacy data will also be collected.
The primary hypotheses for this study are that: 1) the Dose-limiting Toxicities (DLTs)
observed in participants with locally advanced or metastatic solid tumors after
administration of combination therapy with MK-2206 and AZD6244 will be dose-dependent and
allow for identification of the MTD, and 2) oral administration of combination therapy with
MK-2206 and AZD6244 to participants with advanced solid tumors will be generally
well-tolerated.